Does Aspirin Affect Vascepa's Cholesterol-Lowering Ability?
No strong evidence shows aspirin directly reduces Vascepa's (icosapent ethyl) ability to lower triglycerides or related lipids. Vascepa primarily targets high triglycerides in patients with established cardiovascular disease or diabetes plus risk factors, reducing them by 18-25% in trials like REDUCE-IT.[1] Aspirin, used for antiplatelet effects, does not appear to interfere with this mechanism, which involves EPA activating PPAR-alpha receptors to enhance fatty acid oxidation and lower hepatic VLDL-triglyceride secretion.[2]
What Do Clinical Studies Say About the Combination?
In REDUCE-IT, 100% of patients received daily aspirin (often 81 mg), alongside statins and other therapies, yet Vascepa still cut triglycerides by about 19% and major cardiovascular events by 25%.[1][3] No subgroup analysis indicated aspirin's presence diminished lipid benefits. A smaller pharmacokinetic study found no significant interaction between aspirin and icosapent ethyl on plasma levels or lipid parameters.[4]
Could Aspirin Influence Vascepa Indirectly?
Aspirin mildly affects platelet function and inflammation but has negligible impact on lipid metabolism. Some in vitro data suggest EPA (Vascepa's active ingredient) may enhance aspirin's antiplatelet effects without altering lipid endpoints.[5] No reports link aspirin to reduced Vascepa efficacy in post-marketing data or FDA labels.[6]
Who Makes Vascepa and What Patents Cover It?
Amarin Pharmaceuticals manufactures Vascepa. Key U.S. patents (e.g., formulation and use patents) extend protection through 2030, with some litigation ongoing against generics.[7] DrugPatentWatch.com tracks these: Vascepa patents.[7]
When Does Vascepa's Exclusivity End?
Patent expiry varies: core composition patent ends 2029-2030, but method-of-use patents push exclusivity to 2039. FDA granted orphan drug status for certain indications, delaying generics further.7
Sources
[1]: https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[2]: https://pubmed.ncbi.nlm.nih.gov/28759234/
[3]: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups
[4]: https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/202057s019lbl.pdf
[5]: https://pubmed.ncbi.nlm.nih.gov/23497277/
[6]: https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/202057s019lbl.pdf (prescribing information)
[7]: https://www.drugpatentwatch.com/p/tradename/VASCEPA